Search

Your search keyword '"MATSUNAGA, AKIRA"' showing total 143 results
Start Over Author "MATSUNAGA, AKIRA" Publication Year Range Last 10 years
143 results on '"MATSUNAGA, AKIRA"'

13. HIROSHIMA RESEARCH NEWS(12)

Author

KAMIYA, Masamichi, IKEDA, Akifumi, TSUBOUCHI, Jun, MATSUNAGA, Akira, SELF, Benjamin L., SADAMORI, Daiji, KAMIYA, Masamichi, IKEDA, Akifumi, TSUBOUCHI, Jun, MATSUNAGA, Akira, SELF, Benjamin L., and SADAMORI, Daiji

Abstract

A Path to Peace Explored in Hiroshima by Masamichi Kamiya …p.1The U.S. and the Islamic World after the War in Afghanistan by Akifumi Ikeda …p.2 Supremacy Leads to Vulnerability in U.S. Foreign Policy by Jun Tsubouchi …p.2-3HPI Research Forum History and Social Structure of Islamic Fundamentalism…p.3 Bringing China into a Regional Security Framework …p.3U.S.-Middle East Relations after the War in Afghanistan …p.4Research Project on Nuclear Disarmament in the 21st Century : Discussions Preceding the Preparation of the Final Report …p.4-5Research Project on the Legitimacy and Rationality of New-interventionism : Peace Activities and Patterns of International Intervention: A Discussion …p.6Recent Publications by HPI Researchers …p.6-7DIARY…p.8Hello from HPI …p.8, source:http://www.hiroshima-cu.ac.jp/modules/peace_e/index.php

Published
2023

15. Standardization, Trials, and Early Commercialization

Author

Tjelta, Terje, primary, Queseth, Olav, additional, Bourse, Didier, additional, Bellego, Yves, additional, de Peppe, Raffaele, additional, Elshaer, Hisham, additional, Pujol, Frederic, additional, Pearson, Chris, additional, Xiaobei, Chen, additional, Nakamura, Takehiro, additional, Matsunaga, Akira, additional, Yoshino, Hitoshi, additional, Okumura, Yukihiko, additional, Kim, Dong Ku, additional, Park, Jinhyo, additional, and Jeon, Hong Beom, additional

Published
2018
Full Text
View/download PDF

19. Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia

Author

Moriyama, Takahiro, Matsunaga, Akira, Nagata, Osamu, Enohata, Kei, Kamikawaji, Tomomi, Uchino, Erika, and Kanmura, Yuichi

Subjects
Propofol -- Research, Rocuronium bromide -- Research, Neuromuscular blocking agents -- Methods -- Analysis -- Models -- Research -- Dosage and administration, Pharmacokinetics -- Research, Health
Abstract

Background Rocuronium bromide (Rb) is a rapid onset, intermediate-acting neuromuscular blocking agent that is suitable for continuous administration. The appropriate rate of rocuronium administration is, however, difficult to determine due to large interindividual differences in sensitivity to rocuronium. The aim of this study was to clarify whether the simulated rocuronium concentration at the time of recovery to %T1 > 0 % after the initial administration of rocuronium is a good indicator of optimal effect-site concentrations during continuous rocuronium administration. Methods Twenty-one patients were anesthetized with propofol. After induction, Rb 0.6 mg/kg was administered intravenously, and nerve stimulation using the single stimulation mode was conducted every 15 s. When %T1 recovered to >0 % after the initial administration of Rb, the effect-site concentration of rocuronium, calculated by pharmacokinetic simulation with Wierda's set of parameters, was recorded and defined as the recovery concentration (Rb r.c.). The administration rate of rocuronium was adjusted to maintain the Rb r.c. during surgery. Rb administration was discontinued just before the end of surgery, and the recovery time until %T1 > 25 % was recorded. Plasma Rb concentrations were measured at 1 and 3 h after the initiation of continuous Rb administration. Result The mean Rb r.c. was 1.56 ± 0.35 [mu]g/ml, with minimum and maximum values of 1.09 and 2.08 [mu]g/ml, respectively. The %T1 did not increase above 10 % in any of the patients during continuous administration of Rb, and the recovery period to %T1 > 25 % ranged from 9 to 29 min. The effect-site concentrations of Rb calculated with Wierda's parameters significantly correlated with plasma concentrations (P < 0.01) at both 1 and 3 h after the initial administration of Rb. Conclusion The results suggest that our method may be one of the most reliable protocols for the continuous administration of Rb described to date for maintaining suitable muscle relaxation during surgery without excessively prolonged effects., Author(s): Takahiro Moriyama[sup.1] , Akira Matsunaga[sup.1] , Osamu Nagata[sup.1] , Kei Enohata[sup.1] , Tomomi Kamikawaji[sup.1] , Erika Uchino[sup.1] , Yuichi Kanmura[sup.1] Author Affiliations: (1) Department of Anesthesiology and Intensive Care, [...]

Published
2015
Full Text
View/download PDF

21. Emerging resistance to beta-lactams in Pantoea ananatis isolated from an immunocompetent patient with bacteremia

Author

Yoshimura, Michinobu, primary, Tokushige, Chiemi, additional, Maruyama, Jun-ichi, additional, Kawano, Yasumasa, additional, Ishikura, Hiroyasu, additional, Matsunaga, Akira, additional, Takata, Tohru, additional, Hiromatsu, Kenji, additional, Yanagihara, Itaru, additional, Togawa, Atsushi, additional, and Takamatsu, Yasushi, additional

Published
2022
Full Text
View/download PDF

26. Development of Industrial Robot System with 5th Generation Mobile Communication System

Author

Kyushu Institute of Technology, KDDI Co., KDDI Research Inc., Advanced Telecommunications Research Institute International, DENSO Co., Yokota, Atsuki, Honda, Sora, Yamafuku, Kei, Nishida, Takeshi, Ikenaga, Takeshi, Mori, Naoki, Matsunaga, Akira, Maruyama, Kakeru, Yoshida, Kyohiro, Osada, Shintaro, Kyushu Institute of Technology, KDDI Co., KDDI Research Inc., Advanced Telecommunications Research Institute International, DENSO Co., Yokota, Atsuki, Honda, Sora, Yamafuku, Kei, Nishida, Takeshi, Ikenaga, Takeshi, Mori, Naoki, Matsunaga, Akira, Maruyama, Kakeru, Yoshida, Kyohiro, and Osada, Shintaro

Abstract

type:Journal Article, We experimented the configuration of a 5th generation mobile communication system (5G) for factory automation (FA) systems consisting of industrial robots and three-dimensional measurement sensors. We examined the configuration of system components, on the basis of which we developed an experimental FA system. In addition, we confirmed that the need for communication lines is eliminated as 5G greatly reduces the production preparation time when rearranging the parts of the developed FA system., 19th International Conference on Control, Automation and Systems (ICCAS 2019), October 15-18, 2019, Jeju, Korea

Published
2020

37. Additional file 1: of BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

Author

Miyamoto, Shingo, Fusanori Yotsumoto, Ueda, Taeko, Fukami, Tatsuya, Sanui, Ayako, Miyata, Kohei, Nam, Sung, Fukagawa, Satoshi, Katsuta, Takahiro, Maehara, Miyako, Kondo, Haruhiko, Miyahara, Daisuke, Shirota, Kyoko, Yoshizato, Toshiyuki, Kuroki, Masahide, Nishikawa, Hiroaki, Keijiro Saku, Tsuboi, Yoshio, Ishitsuka, Kenji, Takamatsu, Yasushi, Tamura, Kazuo, Matsunaga, Akira, Hachisuga, Toru, Nishino, Shinsuke, Odawara, Takashi, Maeda, Kazuhiro, Manabe, Sadao, Ishikawa, Toyokazu, Okuno, Yoshinobu, Ohishi, Minako, Hikita, Tomoya, Mizushima, Hiroto, Iwamoto, Ryo, and Mekada, Eisuke

Abstract

Table S1. Pharmacokinetics of BK-UM. (PDF 48 kb)

Published
2017
Full Text
View/download PDF

43. BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

Author

Miyamoto, Shingo, primary, Yotsumoto, Fusanori, additional, Ueda, Taeko, additional, Fukami, Tatsuya, additional, Sanui, Ayako, additional, Miyata, Kohei, additional, Nam, Sung Ouk, additional, Fukagawa, Satoshi, additional, Katsuta, Takahiro, additional, Maehara, Miyako, additional, Kondo, Haruhiko, additional, Miyahara, Daisuke, additional, Shirota, Kyoko, additional, Yoshizato, Toshiyuki, additional, Kuroki, Masahide, additional, Nishikawa, Hiroaki, additional, Saku, Keijiro, additional, Tsuboi, Yoshio, additional, Ishitsuka, Kenji, additional, Takamatsu, Yasushi, additional, Tamura, Kazuo, additional, Matsunaga, Akira, additional, Hachisuga, Toru, additional, Nishino, Shinsuke, additional, Odawara, Takashi, additional, Maeda, Kazuhiro, additional, Manabe, Sadao, additional, Ishikawa, Toyokazu, additional, Okuno, Yoshinobu, additional, Ohishi, Minako, additional, Hikita, Tomoya, additional, Mizushima, Hiroto, additional, Iwamoto, Ryo, additional, and Mekada, Eisuke, additional

Published
2017
Full Text
View/download PDF

45. The Change in Body Weight During Hospitalization Predicts Mortality in Patients With Acute Decompensated Heart Failure

Author

Komaki, Tomo, primary, Miura, Shin-ichiro, additional, Arimura, Tadaaki, additional, Shiga, Yuhei, additional, Morii, Joji, additional, Kuwano, Takashi, additional, Imaizumi, Satoshi, additional, Kitajima, Ken, additional, Iwata, Atsushi, additional, Morito, Natsumi, additional, Yahiro, Eiji, additional, Fujimi, Kanta, additional, Matsunaga, Akira, additional, and Saku, Keijiro, additional

Published
2017
Full Text
View/download PDF

47. Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study.

Author

Imaizumi, Satoshi, Shiga, Yuhei, Ogawa, Masahiro, Sako, Hideto, Nagata, Yoshihisa, Matsunaga, Akira, Shirotani, Tetsuro, Hoshino, Fumihiro, Yahiro, Eiji, Uehara, Yuko, Morito, Natsumi, Tanigawa, Hiroyuki, Shimono, Dai, Fukushima, Mikio, Sugihara, Hidekazu, Norimatsu, Kenji, Kusumoto, Takaaki, Saku, Keijiro, and Miura, Shin-ichiro

Subjects
TYPE 2 diabetes, CALCIUM antagonists, ANGIOTENSIN II, ESSENTIAL hypertension, PEOPLE with diabetes
Abstract

There is a lack of data on how to treat hypertensive patients with diabetes when treatment with medium doses of calcium channel blocker and angiotensin II type 1 receptor blocker (ARB) is insufficient to achieve the target blood pressure (BP). A total of 121 participants with type 2 diabetes and uncontrolled essential hypertension, who were receiving medium doses of amlodipine (5 mg/day) and ARB, were enrolled. Participants were randomized to receive either a high dose of amlodipine (10 mg/day) plus a medium dose of ARB (high-AML) or a medium dose of amlodipine (5 mg/day) plus a high dose of ARB (high-ARB). The depressor effects of these two regimens were monitored using a telemonitoring home BP-measuring system. Fifty-four patients were excluded after an observation period, and the remaining 67 eligible participants were randomized into the two groups; 42 which had a record of their home BP for analysis. The change in morning home systolic and diastolic BP was greater in the high-AML than in the high-ARB (systolic BP; − 7.9 mmHg vs. + 2.7 mmHg; p = 0.0002, diastolic BP; − 3.9 mmHg vs. + 0.6 mmHg; p = 0.0007). In addition, the home systolic and diastolic BP before going to bed and office systolic BP were significantly reduced from week 0 only in the high-AML. An increased dose of amlodipine, but not ARB, reduced home morning BP in hypertensive patients with type 2 diabetes who were already receiving combination therapy with medium doses of amlodipine and ARB. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results